Dr Ali Alshahrani
Executive Director of Pharmacovigilance and Acting Executive Director of Drug Evaluation Saudi food and drug authority
Saudi Arabia
Judit Rius Sanjuan
Director, Department of Innovation, Access to Medicines and Health Technologies (IMT) at PAHO/WHO
International
Lovisa Gustafsson
Vice president of the Controlling Health Care Costs program at the Commonwealth Fund
International
Yusi Anggriani
Professor in the Clinical and Community Pharmacy at Universitas Pancasila in Jakarta Indonesia
Indonesia
Dr Quinn Grundy
Assistant Professor with the Lawrence Bloomberg Faculty of Nursing at the University of Toronto
Canada
Dr Andy Gray
Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal
South Africa
Dr Daniela Marreco Cerqueira
Executive Secretary, Medicines Market Regulation Committee (SCMED), Brazilian Health Regulatory Agency [ANVISA]
Brazil
Anchalee Jitruknatee
Director
Division of National Drug Policy, Food and Drug Administration, Thailand
Lisa Hedman
Senior Advisor, WHO Division of Access To Medicines and Health Products (MHP)
International
Victor Mendonca
Chair of the Generic Market Access Committee at Medicines for Europe, and Head of Corporate Affairs Europe, Viatris
International
Dr Prashant Yadav
Affiliate Professor of Technology and Operations at INSEAD and Academic Director of the INSEAD Africa Initiative
France
Dr Joseph S. Ross
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management) at the Yale School of Medicine
United States of America
Dr Graciela Fernández
Doctora en Medicina y Médico Intensivista egresada de la Facultad de Medicina de la Universidad de la República (UdelaR)
Uruguay
Dr Wee Hwee Lin
Associate Professor at the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore
Singapore
Prof Ambroise Wonkam
Professor of Genetic Medicine, and Director of McKusick-Nathans Institute, and Department of Genetic Medicine, Johns Hopkins
Cameroon
Dr Patrice Verpillat
Head of the Real World Evidence (RWE) Workstream at the European Medicines Agency (EMA)
International
Negotiating fair pricing – opportunities, powers, promises
Dr Sabine Vogler
Head of the Pharmacoeconomics Department of the Austrian National Public Health Institute
Austria
Dr Suerie Moon
Co-Director of the Global Health Centre and Professor of Practice in the International Relations/Political Science Department at the Geneva Graduate Institute
Switzerland
Dr Anban Pillay
Deputy Director General at the National Department of Health in South Africa
South Africa
Valérie Paris
Senior policy analyst - Health Division Organisation for Economic Co-operation and Development
International
Anthony D. So
Professor of the Practice at the Johns Hopkins Bloomberg School of Public Health
United States of America
The untapped potential of biosimilars: how to ensure affordable access?
Dr Steven Morgan
Economist and Professor of health care policy at the University of British Columbia
Canada
Advancing accessibility and affordability of medical devices and in vitro diagnostics by bridging the information gap and complexity
Adriana Velazquez Berumen
Senior adviser and team lead of medical devices and in vitro diagnostics at the World Health Organization
International
Andrew Rintoul
Assistant Secretary at the Australian Government Department of Health and Aged Care
Australia
Dr David Henri Beran
Assistant Professor at the Faculty of Medicine at the University of Geneva
International
Dr Stijn Deborggraeve
Diagnostics Advisor Infectious Diseases at Médecins Sans Frontières (MSF) Access Campaign
International
How to pay for universal access to medicines for rare diseases and by whom? The great conundrum
Dr Hana Al-Abdulkarim
Director of Drug Policy and Economic Center DPEC in NGHA (Riyadh, KSA)
Saudi Arabia
Dr Bhagwan Singh Charan
Assistant Director General (ADG) at Directorate General of Health Services, Ministry of Health & Family Welfare Government of India
India
Dr Izzuna Mudla Mohamed Ghazali
Deputy Director of the Medical Development Division, Ministry of Health Malaysia
Malaysia
Sharmila Nebhrajani
Chairman of the National Institute for Health and Care Excellence (NICE)
United Kingdom
Dr Roberto Giugliani
Professor at the Department of Genetics of the Federal University of Rio Grande do Sul (UFRGS)
Brazil
Using HTA to improve affordable access to essential medicines
Dr Mouna Jameleddine
Head of the HTA Department at the Tunisian National Authority for Assessment and Accreditation in Health (INEAS)
Tunisia
Prof Dr Andres Pichon-Riviere
Director of the Health Economics and Technology Assessment Department at the IECS
Argentina
Dr Rabia Sucu
President of Health Technology Assessment International Society and Senior Principal Technical Advisor for Health Policy and Financing in the Management Sciences for Health (MSH)
United States of America
Dr Panos Kanavos
Associate Professor of International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG
United Kingdom
Dr YingYao Chen
Professor of Health Technology Assessment at Fudan University School of Public Health
China
Dr Jacqui Miot
Division Director of the Health Economics and Epidemiology Research Office (HE2RO)
South Africa
Intellectual property challenges to promote innovation and timely global equitable access and affordability
Mustaqeem de Gama
Director of legal international trade, Afrigen/Department of Trade, Industry and Competition
South Africa
Boyan Konstantinov
Policy Specialist, HIV, Health and Development, United Nations Development Programme
International
Paul Fure Torkehagen
Vice President of International Business Development at Medigen Vaccine Biologics Corp
International
Sergiy Kondratyuk
Project Manager, International Treatment Preparedness Coalition (IPTC) Global
Ukraine
Dr Viviana Muñoz Tellez
Programme Coordinator of the Health, Intellectual Property and Biodiversity (HIPB) Programme of the South Centre
International
H.E. Ambassador Shara Duncan-Villalobos
Ambassador Deputy Permanent Representative of Costa Rica to the United Nations Office
Costa Rica
In a post pandemic world, how can policies mitigate drug shortages and increase access to patients while maintaining affordability?
Dr Alejandro Ernesto Svarch Pérez
Head of Commission, Federal Commission for the Protection against Health Risks
Mexico
Abdulrazaq Al-Jazairi
Director, Clinical Trials Transformation Initiative (CTTI) Division. Clinical Pharmacy Consultant, Cardiology
Saudi Arabia
Suzannah Chapman
Health Policy Analyst, Organisation for Economic Co-operation and Development
International
Dr Nehal Gamal El-Din Ebrahim Abou Youssef
Head of administration of Drug availability and business continuity
Egypt
Prof Abderazzek Hedhili
General Director, National regulatory agency of medicines and health products
Tunisia
Mansour Al Howaimel
Senior Manager of pharmacoeconomics department in National Unified Procurement Company
Saudi Arabia
Jim Keon
Canadian Generic Pharmaceutical Association(CGPA)/International Generic and Biosimilar Medicines Association (IGBA)
International
Abdullah H. AL-Hatareshah
Clinical pharmacist and Executive Director for Regulatory Affairs at the Saudi Food and Drug Authority
Saudi Arabia
Optimizing pricing policies and strategies by buyers and sellers—getting it right
Dr Katrina Perehudoff
Health scientist and legal scholar, University of Amsterdam, Kingdom of the Netherlands
Netherlands
Adriana María Robayo García
Executive Director, Instituto de Evaluación Tecnologica en Salud
Colombia
Abraham S.T. Weekes
Senior Technical Specialist at Organization of Eastern Caribbean States Pharmaceutical
International
Dr Veronika Wirtz
Professor of Global Health at the Boston University School of Public Health
United States of America
Francis Arickx
Head of the directorate Reimbursement of Medicines and Pharmaceutical Policy within the Health Care Department at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI)
Belgium
